Erectile dysfunction and phosphodiesterase type 5 inhibitors;La dysfonction érectile masculine et les inhibiteurs de la phosphodiestérase de type 5

Revue Medicale de Bruxelles

Volumn 24, Issue 3, 2003, Pages 169-175

  Roumeguere T ^a   Sternon, J ^a   Schulman, C C ^a  

^a NONE

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

APOMORPHINE; CIMETIDINE; CORVATARD; ERYTHROMYCIN; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MOLSIDOMINE; NYSCONITRINE; PENTETRAZOLE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; SAQUINAVIR; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; WILLONG;

ARTICLE; BELGIUM; DRUG CONTRAINDICATION; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HUMAN; LIFE EXPECTANCY; NAUSEA; NOSE CONGESTION; PHARYNGITIS; PREVALENCE; RELIABILITY; RHINITIS; SIDE EFFECT; VERTIGO; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ENZYME INHIBITORS; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PREVALENCE;

EID: 0038148577     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Feldman H, Goldstein I, Hatzichristou D et al: Impotence and its medical and psychosocial correlates: Results of the Massachussetts male aging study. J Urol 1994; 151: 54-61
2. Mc Kinlay JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int J Imp Res 2000; 12: S6-11
3. Mak R, De Backer G, Kornitzer M et al: Prevalence and correlates of erectile dysfunction in a population-based study in Belgium. Eur Urol 2002; 41: 132-8
4. Cappelleri JC, Rosen RC, Smith MD et al: Diagnostic evaluation of the erectile function: Domain of the International Index of Erectile Function. Urology 1997; 54: 346-54
5. Lue TF: Erectile dysfunction. N Engl J Med 2000; 342: 1802-13
6. Azadzoi K, Saenz de Tejada I: Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1991; 146: 238
7. Rendell MS, Rajfer J, Wicker PA et al: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 1999; 281: 421-6
8. Saenz de Tejada I, Anglin G, Knight JR et al: Effects of Tadalafil on Erectile Dysfunction in Men With Diabetes. Diabetes Care 2002; 25: 2159-64
9. Zusman RM: Cardiovascular data on sildenafil citrate. Am J Cardiol 1999; 83: 1C-2C
10. Montorsi P, Montorsi F, Schulman C: Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? Eur Urol 2003; sous presse
11. Roumeguère T, Bollens R, Wespes E et al: Prevalence of hyperlipidemia and risk of coronary heart disease in a population with erectile dysfunction. J Urol 2001; 165: 171-A 700
12. Roumeguère T, Wespes E, Carpentier Y et al: Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; sous presse
13. Goldstein I, Lue T, Padma-Nathan H et al: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-404
14. Jayet C, Wisard M: Urologie. Med Hyg 2003; 61: 67-70
15. de Busk R, Drory Y, Goldstein I et al: Management of sexual dysfunction in patients with cardiovascular disease. Am J Cardiol 2000; 86: 175-80
16. Andrianne R: Le médicament du mois: Le sildénafil (Viagra ®). Rev Med Liege 1999; 5: 58-61
17. Brock GB, McMahon CG, Chen KK et al: Efficacy and safety of Tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002; 168: 1332-36
18. Porst H, Rosen R, Padma-Nathan H et al: The efficacy and tolerability of vardenafil, a new oral selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 4: 192-9
19. Saenz de Tejada I, Angulo J, Cuevas P et al: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. J Impot Res 2001; 13: 282-90
20. Taladafil (Cialis ®): Un peu plus commode d'emploi, mais peu évalué dans les troubles organiques. Rev Prescr 2003; 23: 325-31
21. El-Galley R, Rutland H, Talic R et al: Long term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001; 166: 927-31
22. Kloner RA, Jarow JP: Erectile Dysfunction and Sildenafil Citrate and Cardiologists. Am J Cardiol 1999; 83: 576-82
23. Rosen R, O'Leary M, Altwein J et al: LUTS and male sexual dysfunction: the multi-national survey of the aging male. Eur Urol 2003; (Suppl 2): abst 365
24. Zlotta A, Schulman CC: BPH and sexuality. Eur Urol 1999; 36 (Suppl 1): 107-12
25. Van Moorselaer R, Emberton M, Harvin N et al: Alfuzosin 10 mg once daily improves sexual function in men with luts and concomitan sexual dysfunction. Eur Urol 2003; 1 (Suppl 2): abst 285
26. Dula E, Bukofzer S, Perdok R et al: Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-3
27. Waldhauser M, Schramek P: Efficiency and side-effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1998; 140: 525-7
28. Porst H: Transurethral alprostadil with MUSE (medical urethral system for erection) vs intravenous intracavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Imp Res 1997; 9: 187-92
29. Seftel AD: Challenges in Oral Therapy for Erectile Dysfunction. J Androl 2002; 23: 729-36
30. Moynihan R: The making of a disease: female sexual dysfunction. BMJ 2003; 326: 45-7
31. Ghofrani HA, Wiedeman R, Rose F et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002; 360: 895-900